Interleukin inhibitors in patients with psoriasis

Authors

Downloads

Download data is not yet available.

Author Biography

Julio Cesar Camero Machín , HOSPITAL CLINICO DOCENTE LEON CUERVO RUBIO

MsC. JULIO CESAR CAMERO MACHIN

ESPECIALISTA 2DO GRADO MGI Y PRIMER GRADO DERMATOLOGIA. INVESTIGADOR AUXILIAR. PROFESOR AUXILIAR

References

1.Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Gerard Egan C. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J Clin Med. 2020 [citado: 20/11/2024];9(7):2170. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7408922/pdf/jcm-09-02170.pdf

2.Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M. The Role of Interleukin 23/17 Axis in Psoriasis. Management: A Comprehensive Review of Clinical. Trials Clinical, Cosmetic and Investigational Dermatology. 2024 [citado: 20/11/2024]; (17):829-42. Disponible en:

https://www.dovepress.com/article/download/91857

3.Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front med ( Lausanne). 2023 [citado: 20/10/2024]; 10(1): 196966. Disponible en:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10352451/pdf/fmed-10-1196966.pdf

Downloads

Published

2025-09-18

How to Cite

1.
Camero Machín JC. Interleukin inhibitors in patients with psoriasis. MEDISAN [Internet]. 2025 Sep. 18 [cited 2025 Oct. 6];29:e5155. Available from: https://medisan.sld.cu/index.php/san/article/view/5155

Issue

Vol. 29 (2025): publicación continua

Section

Letters

License

Copyright (c) 2025 MEDISAN

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.